UNITY Biotechnology Inc: Ongoing Phase 2B Aspire Study of Ubx1325 Has Been Extended From 24 to 36 Weeks
UNITY Biotechnology Inc:正在進行的Ubx1325的2B期Aspire研究已從24周延長至36周
UNITY Biotechnology Inc: Ongoing Phase 2B Aspire Study of Ubx1325 Has Been Extended From 24 to 36 Weeks
UNITY Biotechnology Inc:正在進行的Ubx1325的2B期Aspire研究已從24周延長至36周
使用瀏覽器的分享功能,分享給你的好友吧